Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACAT1 | P24752 | 1/20 | 0.52 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | EDNRB | P24530 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6638660 | 0.97 | ACAT1 (0.49) | ACAT1SOAT1KDM4EHSD17B10EDNRB | |
| SCHEMBL7734565 | 0.92 | ACAT1 (0.53) | ACAT1SOAT1PDE4APDE4BPDE4C | |
| SCHEMBL7613883 | 0.91 | ACAT1 (0.46) | ACAT1SOAT1EDNRB | |
| SCHEMBL7735514 | 0.90 | ACAT1 (0.50) | ACAT1SOAT1KDM4EHSD17B10 | |
| SCHEMBL6636150 | 0.90 | EDNRB (0.49) | ACAT1SOAT1EDNRB | |
| SCHEMBL7610547 | 0.89 | EDNRB (0.49) | KDM4EHSD17B10EDNRBPDE4APDE4B | |
| SCHEMBL6635742 | 0.89 | SOAT1 (0.45) | ACAT1SOAT1EDNRB | |
| SCHEMBL6634385 | 0.88 | EDNRB (0.46) | ACAT1SOAT1EDNRB | |
| SCHEMBL8325657 | 0.87 | PDE4A (0.47) | ACAT1SOAT1PDE4APDE4BPDE4C | |
| SCHEMBL6639134 | 0.87 | EDNRB (0.44) | ACAT1SOAT1EDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0842933-B1 | NOVEL NAPHTHYRIDINE DERIVATIVES | SUMITOMO PHARMA (JP) | 2004-08-04 | — | — | EP | disclosed |
| US-6452008-B2 | 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-09-17 | — | — | US | disclosed |
| US-6420381-B1 | ACYL-COA: CHOLESTEROL ACYL TRANSFERASE (ACAT) INHIBITORY ACTIVITY, AND IS USEFUL AS AN AGENT FOR TREATMENT OF HYPERLIPIDEMIA AND ATHEROSCLEROSIS. | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-07-16 | — | — | US | disclosed |
| US-20010051732-A1 | Pyridone derivatives and process for preparing the same | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2001-12-13 | — | — | US | disclosed |
| US-6300500-B1 | Preparation of pyridone derivatives using phthalimido containing starting material | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-10-09 | — | — | US | disclosed |
| EP-1104763-A1 | NAPHTHYRIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-06-06 | — | — | EP | disclosed |
| CN-1065243-C | Naphthyridine derivs. | SUMITOMO PHARMA (JP) | 2001-05-02 | — | — | CN | disclosed |
| EP-1086948-A1 | PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-03-28 | — | — | EP | disclosed |
| EP-0947515-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1999-10-06 | — | — | EP | disclosed |
| US-5843957-A | Naphthyridine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LTD. (JP) | 1998-12-01 | — | — | US | disclosed |
| EP-0842933-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051732-A1 | Pyridone derivatives and process for preparing the same | HK1, HPD, ALK | ACAT1 1776/4885SOAT1 2578/4885KDM4E 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.